Skip to Content

Posts tagged with "Cancer"

  • Biological News

    MAGL: A New Cancer Target

    I do enjoy some good chemical biology, and the latest Cell has another good example from the Cravatt group at Scripps (working with a team at Brigham and Women’s Hospital over here on this coast). What they’ve done is profile various types of tumor cells using an activity-based probe to search for changes in serine… Read More
  • Biological News

    Is XMRV the Cause of Chronic Fatigue Syndrome? Or Anything?

    Last fall it was reported that a large proportion of patients suffering from chronic fatigue syndrome also showed positive for a little-understood retrovirus (XMRV). This created a lot of understandable excitement for sufferers of a conditions that (although often ill-defined) seems to have some puzzling biology buried in it somewhere. Well, let th… Read More
  • Aging and Lifespan

    A Nobel for Telomerase

    As many had expected, a Nobel Prize has been awarded to Elizabeth Blackburn (of UCSF), Carol Greider (of Johns Hopkins), and Jack Szostak (of Harvard Medical School/Howard Hughes Inst.) for their work on telomerase. Blackburn had been studying telomeres since her postdoc days in the late 1970s, and she and Szostak worked together in the… Read More
  • Biological News

    Antioxidants and Cancer: Backwards?

    Readers may remember a study from earlier this year that suggested that taking antioxidants canceled out some of the benefits of exercise. It seems that the reactive oxygen species themselves, which everyone’s been assuming have to be fought, are actually being used to signal the body’s metabolic changes. Now there’s another distu… Read More
  • Cancer

    Thalidomide for Myeloma: Whose Idea Was It?

    So, if you’re a patient with a rare disease (or a relative of a patient with one), and you have an idea for repurposing an old drug for treatment. . .and you get a company interested, and it actually works. . .works to the point that the company takes in a billion or two dollars… Read More
  • Academia (vs. Industry)

    Wasted Money, Wasted Time?

    Now, while we’ve been talking about how much basic research is done in industry, or how much clinical research gets done in academia, here’s something that might bear on the discussion. Too much of what looks like useful clinical research on the academic side is actually wasted effort. The New York Times has been running… Read More
  • Cancer

    Avastin’s Numbers

    Here’s a fascinating (and alarming) look at the clinical data from the recent trial of Avastin (bevacizumab) in adjuvant colorectal cancer (that is, post-surgical therapy). This was an issue in the recent Roche/Genentech takeover, since it could significantly enlarge the market for the drug. According to the In Vivo Blog, the one-year interim… Read More
  • Business and Markets

    Akt and Mek, But Not PDQ

    Well, the ASCO meeting has been roaring along, with dozens of press releases coming out. (Go to Google News and type that acronym in if you want to get the full experience). They range from the pretty-interesting to the despair-inducing, but one bit of news struck me as particularly worth noting. That’s the early-stage deal… Read More
  • Cancer

    But You Can’t Make Them Take It?

    Well, we can all study biochemical mechanisms in tumor cells every day of the week. And we can crank out tens of thousands of potential clinical candidates to hit them, run the assays, and then turn around and do it again. We can send things through all sorts of tox testing, take them to the… Read More
  • Cancer

    Angiogenesis Inhibitors: Helping or Hurting?

    Now, here’s something to think about: can angiogenesis inhibitors, the famous class of tumor-starving cancer drugs, actually make some kinds of cancer worse? This unnerving thought comes courtesy of two recent studies on VEGF pathway inhibitors which present what… Read More